# Targeted Platinum Drugs for Cancer Treatment > This patent describes a way to deliver platinum-based cancer drugs directly to tumor cells by attaching them to a special 'ligand' molecule that seeks out cancer cell markers. - **Patent:** US 9884123 - **Original title:** Ligand-targeted molecules and methods thereof - **Owner:** INVICTUS ONCOLOGY PVT - **Granted:** 2018 - **Status:** Active - **Times cited:** 3 - **Field:** biotech, pharmaceutical, oncology, drug_delivery, chemistry ## What it does This patent describes a 'ligand drug conjugate' (LDC) designed to deliver chemotherapy drugs specifically to cancer cells. The LDC works by connecting a 'ligand' (a molecule that can find and stick to specific targets) to a 'functional moiety,' which is then linked to a 'coordination metal complex' containing platinum (II). This platinum complex is, in turn, connected to a drug. The ligand is designed to bind to a 'protein, receptor, or cell marker on a surface of a cancer cell' (claims 2, 9), acting like a homing beacon. The connections between these parts are made by 'linkers,' which can be simple chains like hydrocarbons or more complex ones like polyethylene glycol (PEG), amino acids, or peptides (claims 3, 10). For example, a ligand might specifically recognize a unique protein found only on the surface of lung cancer cells, guiding the attached platinum drug directly to those cells to treat the cancer (claims 5, 11) while minimizing harm to healthy tissues. ## What it does NOT cover - Does not cover non-targeted platinum drugs that distribute throughout the body without a specific cancer cell homing mechanism. - Does not cover targeted drug conjugates that use metal complexes other than platinum (II) as the central coordination component. - Does not cover targeted drug conjugates where the drug is not connected via a platinum (II) coordination complex. - Does not cover methods of treating diseases other than cancer using these specific conjugates. - Does not cover targeting mechanisms that do not involve a ligand binding to a protein, receptor, or cell marker on a cancer cell's surface. ## The clever bit The clever part is the specific chemical architecture of the drug conjugate, particularly the inclusion of a platinum (II) coordination complex as a central, structured component that links the drug to the targeting ligand. This design allows for the precise, targeted delivery of platinum-based chemotherapy agents, aiming to improve their therapeutic index by localizing their activity. ## Real-world examples 1. Cisplatin (a non-targeted platinum drug) 2. Carboplatin (another non-targeted platinum drug) 3. Antibody-drug conjugates (ADCs) in cancer therapy 4. Targeted chemotherapy for solid tumors ## Why it matters Traditional platinum-based chemotherapy drugs are effective against many cancers but often cause severe side effects because they harm healthy cells along with cancer cells. This patent addresses that problem by proposing a way to target these powerful drugs directly to tumors. By concentrating the drug at the cancer site, it aims to increase effectiveness while reducing harmful side effects, which is a major goal in modern oncology. ## Frequently asked questions ### What does Targeted Platinum Drugs for Cancer Treatment cover? This patent describes a way to deliver platinum-based cancer drugs directly to tumor cells by attaching them to a special 'ligand' molecule that seeks out cancer cell markers. ### Who owns patent US 9884123? INVICTUS ONCOLOGY PVT owns this patent, granted in 2018. ### When does this patent expire? This patent is expected to expire on January 3, 2033, when the invention enters the public domain. ### What is patent US 9884123 cited by? This patent has been cited by 3 later patents that build on its ideas. ### What problem does this patent solve? Traditional platinum-based chemotherapy drugs are effective against many cancers but often cause severe side effects because they harm healthy cells along with cancer cells. This patent addresses that problem by proposing a way to target these powerful drugs directly to tumors. By concentrating the drug at the cancer site, it aims to increase effectiveness while reducing harmful side effects, which is a major goal in modern oncology. ### What does this patent NOT cover? Does not cover non-targeted platinum drugs that distribute throughout the body without a specific cancer cell homing mechanism. **Full plain-English explainer:** https://patentbrief.org/patent/us/9884123/ligand-targeted-molecules-and-methods-thereof **Original patent:** https://patents.google.com/patent/US9884123 --- _Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._ ## Related patents Semantically similar inventions in the PatentBrief corpus: - [Making Cancer-Fighting Antibody Drugs Safer with Precise Attachment](https://patentbrief.org/patent/us/12121527/anthracycline-based-antibody-drug-conjugates-having-high-in-vivo-tolerability) — This patent describes a specific way to build antibody-drug conjugates (ADCs) for cancer treatment by precisely attaching chemotherapy drugs to antibodies to make them safer inside the body. - [Making Drug Proteins Last Longer and Target Diseases Better](https://patentbrief.org/patent/us/20190160160/methods-to-treat-diseases-with-protein-peptide-and-antigen-modification) — This patent describes ways to make protein and peptide drugs stay in the body longer and target specific diseases like autoimmune conditions or cancer more precisely by linking them together or combining them with other molecules. - [How to Build Smaller, Synthetic Antibody-Like Molecules for Medicine](https://patentbrief.org/patent/us/5455030/immunotheraphy-using-single-chain-polypeptide-binding-molecules) — This patent describes a way to create small, single-chain proteins that mimic the binding power of full-sized antibodies to deliver medicine more effectively. - [How Genentech's Antibody Targets Cancerous B Cells](https://patentbrief.org/patent/us/9845355/tecentriq-atezolizumab) — This patent describes a specific humanized antibody designed to bind to a protein called CD79b, which is found on the surface of certain cancer cells. - [How a Specific Protein Fragment Can Train Immune Cells to Fight Cancer](https://patentbrief.org/patent/us/10314897/peptides-and-combination-of-peptides-for-use-in-immunotherapy-against-various-ca) — This patent describes methods to fight various cancers by using a specific protein fragment (peptide LYHDIFSRL) to train a patient's immune cells to recognize and attack tumor cells.